Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569905 | 0.93 | CES2 (0.68) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL13475578 | 0.82 | CES2 (0.64) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL29109649 | 0.82 | CES2 (0.64) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL2883914 | 0.82 | ALDH1A1 (0.68) | CES2CES1HPGDALDH1A1MAPT | |
| SCHEMBL3601971 | 0.80 | CES2 (0.61) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL6947709 | 0.80 | CES2 (0.61) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL29664937 | 0.80 | CES2 (0.61) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL13475579 | 0.80 | CES2 (0.68) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL1246801 | 0.80 | CES2 (0.61) | CES2CES1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL27658812 | 0.80 | CES2 (0.61) | CES2CES1HPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3858909-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | ADEKA CORPORATION (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112839988-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2021-05-25 | — | — | CN | disclosed |
| WO-2020067144-A1 | NUCLEATING AGNET, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | 株式会社ADEKA | 2020-04-02 | — | — | WO | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395209-A1 | NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF | NOC2L, RIF1, NAP1L1 | CES2 4250/4885CES1 4213/4885HPGD 3069/4885 |
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | CES2 2065/4885CES1 2124/4885HPGD 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.